Skip to main content
fr
en
Main navigation
Company
Company profile
Management
Leadership Team
Board of Directors
Strategic Advisory Board
Our history
Science
Scientific approach
Antibody formats
Publications
Products
Pipeline overview
------------------
Lacutamab
IPH4502
Monalizumab
Other Clinical Stage Assets
IPH6501
IPH6101
IPH6401
IPH5201
IPH5301
Partnering
Investors
Overview
News
Events
Stock Info
Share Information
Stock Quote & Chart
Analyst Coverage
Financial and Regulatory Information
Financial Reports
SEC Filings
Articles of Association
Number of Shares and Voting Rights
Share Repurchase Liquidity Agreement
Prospectus Related to Public Offering
Appraiser Reports
Regulated Agreements
General Shareholders Meeting
Governance
Corporate Governance
Management Team
Resources
Investor Email Alerts
Media
Media hub
All press releases
Media center
Careers
Menu
Home
Lettre de mai 2022
Sun, 05/01/2022 - 00:00
Link
Consulter
Company
Company profile
Management
Leadership Team
Board of Directors
Strategic Advisory Board
Our history
Science
Scientific approach
Antibody formats
Publications
Products
Pipeline overview
------------------
Lacutamab
IPH4502
Monalizumab
Other Clinical Stage Assets
IPH6501
IPH6101
IPH6401
IPH5201
IPH5301
Partnering
Investors
Overview
News
Events
Stock Info
Share Information
Stock Quote & Chart
Analyst Coverage
Financial and Regulatory Information
Financial Reports
SEC Filings
Articles of Association
Number of Shares and Voting Rights
Share Repurchase Liquidity Agreement
Prospectus Related to Public Offering
Appraiser Reports
Regulated Agreements
General Shareholders Meeting
Governance
Corporate Governance
Management Team
Resources
Investor Email Alerts
Media
Media hub
All press releases
Media center
Careers
